Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). Article

Sulman, Erik P, Won, Minhee, Blumenthal, Deborah T et al. (2013). Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). . JOURNAL OF CLINICAL ONCOLOGY, 31(18_suppl), lba2010-lba2010. 10.1200/jco.2013.31.18_suppl.lba2010

cited authors

  • Sulman, Erik P; Won, Minhee; Blumenthal, Deborah T; Vogelbaum, Michael A; Colman, Howard; Jenkins, Robert B; Chakravarti, Arnab; Jeraj, Robert; Brown, Paul D; Jaeckle, Kurt A; Schiff, David; Dignam, James; Atkins, James Norman; Brachman, David; Werner-Wasik, Maria; Komaki, Ritsuko; Gilbert, Mark R; Mehta, Minesh P; Aldape, Kenneth D

authors

publication date

  • June 20, 2013

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Genetics
  • Rare Diseases

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • lba2010

end page

  • lba2010

volume

  • 31

issue

  • 18_suppl